HRP20230481T1 - Čvrsti oblici inhibitora ttk - Google Patents
Čvrsti oblici inhibitora ttk Download PDFInfo
- Publication number
- HRP20230481T1 HRP20230481T1 HRP20230481TT HRP20230481T HRP20230481T1 HR P20230481 T1 HRP20230481 T1 HR P20230481T1 HR P20230481T T HRP20230481T T HR P20230481TT HR P20230481 T HRP20230481 T HR P20230481T HR P20230481 T1 HRP20230481 T1 HR P20230481T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystal
- hydrobromide salt
- compound
- cancer
- phosphoric acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363424P | 2016-07-18 | 2016-07-18 | |
| PCT/CA2017/050848 WO2018014116A1 (en) | 2016-07-18 | 2017-07-13 | Solid forms of ttk inhibitor |
| EP17830139.6A EP3484888B1 (en) | 2016-07-18 | 2017-07-13 | Solid forms of ttk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230481T1 true HRP20230481T1 (hr) | 2023-07-21 |
Family
ID=60991755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230481TT HRP20230481T1 (hr) | 2016-07-18 | 2017-07-13 | Čvrsti oblici inhibitora ttk |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10584130B2 (https=) |
| EP (1) | EP3484888B1 (https=) |
| JP (2) | JP6961675B2 (https=) |
| KR (2) | KR102700233B1 (https=) |
| CN (2) | CN115093416B (https=) |
| AU (2) | AU2017299850B2 (https=) |
| BR (1) | BR112019000813A2 (https=) |
| DK (1) | DK3484888T3 (https=) |
| ES (1) | ES2945108T3 (https=) |
| FI (1) | FI3484888T5 (https=) |
| HR (1) | HRP20230481T1 (https=) |
| HU (1) | HUE061872T2 (https=) |
| IL (1) | IL264173B2 (https=) |
| LT (1) | LT3484888T (https=) |
| MA (1) | MA45691A (https=) |
| MX (2) | MX385289B (https=) |
| PL (1) | PL3484888T3 (https=) |
| PT (1) | PT3484888T (https=) |
| RS (1) | RS64210B1 (https=) |
| RU (2) | RU2753905C2 (https=) |
| SG (2) | SG10202103332UA (https=) |
| SI (1) | SI3484888T1 (https=) |
| SM (1) | SMT202300156T1 (https=) |
| TW (2) | TWI745400B (https=) |
| WO (1) | WO2018014116A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017299850B2 (en) | 2016-07-18 | 2021-05-27 | University Health Network | Solid forms of TTK inhibitor |
| KR20240175121A (ko) | 2023-06-12 | 2024-12-19 | 한국재료연구원 | 희토류 산화물을 이용한 입계확산물질의 제조방법 및 이를 이용한 R-Fe-B계 영구자석의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2438092C (en) | 2001-02-21 | 2011-08-09 | Chiron Corporation | Ttk in diagnosis and as a therapeutic target in cancer |
| ATE482213T1 (de) * | 2004-11-04 | 2010-10-15 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine |
| TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| CN103415518A (zh) * | 2010-12-17 | 2013-11-27 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 |
| US9573954B2 (en) * | 2012-11-16 | 2017-02-21 | University Health Network | Pyrazolopyrimidine compounds |
| JP6095857B2 (ja) * | 2013-11-15 | 2017-03-15 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
| AU2017299850B2 (en) | 2016-07-18 | 2021-05-27 | University Health Network | Solid forms of TTK inhibitor |
-
2017
- 2017-07-13 AU AU2017299850A patent/AU2017299850B2/en active Active
- 2017-07-13 ES ES17830139T patent/ES2945108T3/es active Active
- 2017-07-13 JP JP2019501928A patent/JP6961675B2/ja active Active
- 2017-07-13 EP EP17830139.6A patent/EP3484888B1/en active Active
- 2017-07-13 HR HRP20230481TT patent/HRP20230481T1/hr unknown
- 2017-07-13 CN CN202210644487.1A patent/CN115093416B/zh active Active
- 2017-07-13 SI SI201731352T patent/SI3484888T1/sl unknown
- 2017-07-13 KR KR1020237017039A patent/KR102700233B1/ko active Active
- 2017-07-13 SG SG10202103332UA patent/SG10202103332UA/en unknown
- 2017-07-13 BR BR112019000813-6A patent/BR112019000813A2/pt active Search and Examination
- 2017-07-13 FI FIEP17830139.6T patent/FI3484888T5/fi active
- 2017-07-13 RU RU2019101109A patent/RU2753905C2/ru active
- 2017-07-13 CN CN201780043473.1A patent/CN109476667B/zh active Active
- 2017-07-13 SG SG11201900113UA patent/SG11201900113UA/en unknown
- 2017-07-13 IL IL264173A patent/IL264173B2/en unknown
- 2017-07-13 HU HUE17830139A patent/HUE061872T2/hu unknown
- 2017-07-13 US US16/318,426 patent/US10584130B2/en active Active
- 2017-07-13 KR KR1020197001829A patent/KR102537088B1/ko active Active
- 2017-07-13 MA MA045691A patent/MA45691A/fr unknown
- 2017-07-13 PT PT178301396T patent/PT3484888T/pt unknown
- 2017-07-13 RU RU2021124795A patent/RU2021124795A/ru unknown
- 2017-07-13 RS RS20230383A patent/RS64210B1/sr unknown
- 2017-07-13 MX MX2019000744A patent/MX385289B/es unknown
- 2017-07-13 WO PCT/CA2017/050848 patent/WO2018014116A1/en not_active Ceased
- 2017-07-13 LT LTEPPCT/CA2017/050848T patent/LT3484888T/lt unknown
- 2017-07-13 PL PL17830139.6T patent/PL3484888T3/pl unknown
- 2017-07-13 SM SM20230156T patent/SMT202300156T1/it unknown
- 2017-07-13 DK DK17830139.6T patent/DK3484888T3/da active
- 2017-07-18 TW TW106123975A patent/TWI745400B/zh active
- 2017-07-18 TW TW110137560A patent/TWI824313B/zh active
-
2019
- 2019-01-17 MX MX2021008658A patent/MX2021008658A/es unknown
-
2020
- 2020-03-02 US US16/806,392 patent/US11104681B2/en active Active
-
2021
- 2021-08-24 AU AU2021221447A patent/AU2021221447B2/en active Active
- 2021-08-27 US US17/459,725 patent/US11878980B2/en active Active
- 2021-10-13 JP JP2021167806A patent/JP7263473B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI823164B (zh) | 用於製備有療效化合物之方法及中間物 | |
| RU2016151208A (ru) | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы | |
| WO2014043706A8 (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| HRP20220628T1 (hr) | Postupci i međuprodukti za pripremu lijeka | |
| HRP20201582T1 (hr) | Polimorf sik inhibitora | |
| JP2018520205A5 (https=) | ||
| SI2934145T1 (en) | Histone demethylase inhibitors | |
| HRP20161742T4 (hr) | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona | |
| ME02407B (me) | Soli i solvati derivata tetrahidroizohinolina | |
| EA201391522A1 (ru) | Способ получения соединений для применения в качестве ингибиторов sglt2 | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| JP2016537346A5 (https=) | ||
| JP2013542935A5 (https=) | ||
| MX355436B (es) | Sal novedosa de abexinostato, forma cristalina asociada, método de preparacion de la misma y las composiciones farmaceuticas que contienen la misma. | |
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| MX2016001096A (es) | Sales de dasatinib en forma amorfa. | |
| BR112021024533A2 (pt) | Método de síntese de composto de furoimidazopiridina, forma cristalina de composto de furoimidazopiridina, e forma cristalina de sal do mesmo | |
| HRP20230481T1 (hr) | Čvrsti oblici inhibitora ttk | |
| MX2016001095A (es) | Sales de dasatinib en forma cristalina. | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| NZ700221A (en) | Ralfinamide methanesulfonate salts | |
| TN2016000269A1 (en) | Water soluble crystallin salts of certain harringtonines unambiguously protonated on their alkaloid nitrogen and their use as chemotherapeutic drugs. | |
| MD4350B1 (ro) | Forma cristalină delta a sării de L-arginină a perindoprilului, procedeu de obţinere a ei şi compoziţii farmaceutice care o conţin | |
| Nikitina et al. | Novel heterometallic Cu (II)/Cr (III) complex with unique open-chain N-ligand produced in conditions of direct template synthesis | |
| EP4549450A3 (en) | Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts |